EIKN News & Events

Eikon Therapeutics announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, including updated data for its EIK1001 trial in non-small cell lung cancer, NSCLC, and its highly selective PARP1 inhibitor EIK1003. Updated data from its ongoing Phase 2 trial evaluating the safety and tolerability of EIK1001 in combination with both pembrolizumab and histology appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC, also known as its TeLuRide-005 trial, provide evidence of a potentially durable effect of EIK1001 in combination with standard of care, and a preliminary tolerability profile supportive of systemic administration in an out-patient setting, a potential key differentiator of EIK1001 from previous TLR7/8 targeted therapies. EIK1003 Clinical Update: Updated data from EIK1003-001, our Phase 1/2 trial evaluating the safety and efficacy of EIK1003 as monotherapy or in combination with anti-cancer agents in participants with advanced solid tumors, demonstrate that EIK1003 monotherapy was generally well-tolerated across multiple dose levels. In Cohort 1C, signals of antitumor activity were observed with EIK1003 in combination with weekly paclitaxel, with a combination safety profile consistent with paclitaxel's known toxicities. These data support what appears to be a unique profile for EIK1003 in combination strategies within the evolving PARP inhibitor landscape.

Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and development, enters the market with a pitch that its generative biology platform can accelerate and broaden therapeutic discovery.LATEST IPOS AND DIRECT LISTINGS:Generate Biomedicinesopened on February 27 at $15.00. The company priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Generate Biomedicines is a clinical-stage generative biology company that says it is "pioneering the AI revolution in biotechnology and drug design and development."RECENT SPAC IPOS:Fortress Value Acquisition Vopened on February 26 at $10, after it priced its initial public offering of 25M Class A ordinary shares at a price of $10.00 per share.APEX Tech Acquisitionopened on February 26 at $9.98, after it priced its initial public offering of 10M units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-fourth of one ordinary share upon the consummation of an initial business combination.MOZAYYX Acquisitionopened on February 25 at $9.96, after it priced its upsized initial public offering of 26.1M units at $10.00 per unit.ClearThink 1 Acquisitionopened on February 24 at $9.95, after it priced its initial public offering of 12.5M units at $10.00 per unit.PERFORMANCE:Price as of 11:00 am ET on Monday, March 2 -Generate Biomedicines – up over 6% at $13.48.RECENT IPOS TO WATCH:Forgent Power Solutions, Eikon Therapeutics, Bob's Discount Furniture, and Veradermicsare already seeing coverage roll out, while SpyGlass Pharma, Agomaband Once Upon A Farmare among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Liftoff, Cerebras Systems, ayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Liftoff Mobile- The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The company is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.